0001628280-23-030373.txt : 20230823 0001628280-23-030373.hdr.sgml : 20230823 20230823160135 ACCESSION NUMBER: 0001628280-23-030373 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230817 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230823 DATE AS OF CHANGE: 20230823 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Mirati Therapeutics, Inc. CENTRAL INDEX KEY: 0001576263 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462693615 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35921 FILM NUMBER: 231197570 BUSINESS ADDRESS: STREET 1: 3545 CRAY COURT CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-332-3410 MAIL ADDRESS: STREET 1: 3545 CRAY COURT CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 mrtx-20230817.htm 8-K mrtx-20230817
0001576263false00015762632023-05-242023-05-24

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 17, 2023
 
 
MIRATI THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
 
  

Delaware 001-35921 46-2693615
(State of incorporation) (Commission File No.) (IRS Employer Identification No.)

3545 Cray Court, San Diego, California 92121
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (858) 332-3410
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading SymbolName of Each Exchange on Which Registered
Common StockMRTXThe Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐




Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 17, 2023, Laurie Stelzer notified Mirati Therapeutics, Inc. (the “Company”) of her intention to resign from her position as the Company’s Chief Financial Officer and principal financial and accounting officer, effective as of September 8, 2023 (the “Separation Date”), in order to pursue an opportunity with another biotechnology company.

Ms. Stelzer has agreed to provide transition consulting services (the “Consulting Services”) to the Company for an initial term of 60 days following the Separation Date. As consideration for providing the Consulting Services, the Company will pay Ms. Stelzer $10,000 per month and her outstanding equity awards will continue to vest pursuant to their terms.

On August 21, 2023, the Board of Directors of the Company (the “Board”) appointed Aaron Ondrey, the Company’s Senior Vice President, Financial Planning and Analysis, as the Company’s Interim Chief Financial Officer and principal financial officer, effective as of the Separation Date.

Mr. Ondrey, age 47, has served as the Company’s Senior Vice President, Financial Planning and Analysis since July 2022. Prior to joining the Company Mr. Ondrey served as Vice President, Finance of Arena Pharmaceuticals, Inc., a public biotechnology company (acquired by Pfizer Inc. in March 2022) from January 2020 until July 2022. From December 2018 to January 2020, Mr. Ondrey served as Head of Global Commercial Finance at Alexion Pharmaceuticals, Inc., a public biotechnology company (acquired by AstraZeneca in July 2021). From March 2010 to November 2018, Mr. Ondrey served in various finance roles of increasing responsibility, most recently as Executive Director, Commercial Finance and Business Planning, at Regeneron Pharmaceuticals, Inc., a public biotechnology company. Mr. Ondrey received his Bachelor of Science in Business Administration and Finance from Case Western Reserve University.

In connection with Mr. Ondrey’s appointment, the Company has agreed, effective as of the Separation Date, to (i) increase Mr. Ondrey’s annual base salary to $450,000, (ii) the severance benefits provided under the Company’s Executive Severance Plan (which was filed as exhibit 10.31 to the Company’s Annual Report on Form 10-K on February 28, 2023) for so long as Mr. Ondrey serves as Interim Chief Financial Officer and for a period of 90 calendar days thereafter, and (iii) a retention award (the “Retention Award”) comprised of (a) $300,000 in cash and (b) a restricted stock unit award with a $300,000 target value, with the number of shares to be calculated based on the Company’s closing price on September 8, 2023. The Retention Award will vest and be payable in full on the date that is 90 calendar days following the date that a permanent Chief Financial Officer commences employment with the Company (the “Vesting Date”), subject to Mr. Ondrey’s continuous service through such date. The Retention Award will vest and be payable in full if Mr. Ondrey’s employment with the Company is terminated without Cause (as defined under the Company 2022 Equity Incentive Plan) prior to the Vesting Date. Mr. Ondrey’s employment is at-will and may be terminated at any time by either Mr. Ondrey or by us with or without Cause and without notice.

Mr. Ondrey has no family relationships with any of the Company’s directors or executive officers, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. In addition, there are no arrangements or understandings between Mr. Ondrey and any other person pursuant to which he was selected to his roles with the Company.

Item 7.01Regulation FD Disclosure.
On August 23, 2023, the Company issued a press release announcing Ms. Stelzer’s resignation and the appointment of Mr. Ondrey. A copy of this press release is attached hereto as Exhibit 99.1.

The information in this Item 7.01, including the press release attached as Exhibit 99.1, shall not be deemed “filed” for the purposes of or otherwise subject to the liabilities under Section 18 of the Exchange Act. Unless expressly incorporated into a filing of the Company under the Securities Act or the Exchange Act, the information contained in this Item 7.01, including the press release attached as Exhibit 99.1, shall not be incorporated by reference into any Company filing, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 
104Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
    
Date: August 23, 2023 Mirati Therapeutics, Inc.
  
  By:/s/ John B. Moriarty, Jr.
   John B. Moriarty, Jr.
   Chief Legal Officer & Corporate Secretary



 EX-99.1 2 exhibit991-cfotransitionpr.htm EX-99.1 Document


Exhibit 99.1

image_0.jpg
Mirati Therapeutics Announces Departure of Chief Financial Officer Laurie Stelzer
SAN DIEGO, Calif., August 23, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that Laurie Stelzer, Chief Financial Officer, will depart the company on September 8, 2023, to pursue an external opportunity. Aaron Ondrey, senior vice president, financial planning and analysis (FP&A), Mirati Therapeutics, will assume the role of interim CFO. Ms. Stelzer will remain as a consultant to the company through October 2023.
“On behalf of the Board and the Company, we thank Laurie for her leadership and the contributions made during her tenure,” said Charles M. Baum, M.D., Ph.D., interim CEO, president and founder, Mirati Therapeutics.
“It has been a privilege to serve as CFO of Mirati and I am grateful for the opportunity and the experience to work alongside a team committed to positively impacting the lives of patients,” said Laurie Stelzer, chief financial officer, Mirati Therapeutics. “The caliber, commitment and expertise of the Mirati team will continue to inspire me. I look forward to the Company’s future success.”
Mr. Ondrey joined Mirati as senior vice president, FP&A, in July of 2022, bringing over 20 years of experience in financial management, strategic planning, capital allocation and mergers and acquisitions. Previously, he held senior leadership roles at Arena Pharmaceutics, Inc., Alexion Pharmaceuticals, Inc. and Regeneron Pharmaceuticals, Inc.
Mirati recently completed an upsized public offering, further extending the Company’s cash runway ahead of several upcoming milestones.
About Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc. is a commercial stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. Unified for patients, Mirati's vision is to unlock the science behind the promise of a life beyond cancer.
For more information about Mirati, visit us at Mirati.com or follow us on Twitter, LinkedIn and Facebook. 
Forward Looking Statements
This press release includes forward-looking statements regarding Mirati's business, financial guidance and the therapeutic and commercial potential of KRAZATI® (adagrasib), MRTX1719 (MTA-cooperative PRMT5 inhibitor), MRTX0902 (SOS1 inhibitor), and MRTX1133 (selective KRASG12D inhibitor), Mirati's technologies and Mirati's other products in development. Any statement describing Mirati's goals, expectations, intentions or beliefs, financial or other projections, is a forward-looking statement and should be considered an at-risk statement. Such


statements are subject to certain risks and uncertainties including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines.
Mirati's forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Mirati's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Mirati. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Mirati's programs are described in additional detail in Mirati's annual report on Form 10-K, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission and available at the SEC's Internet site (https://www.sec.gov/). These forward-looking statements are made as of the date of this press release, and Mirati assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.
Mirati Contacts
Investor Relations: ir@mirati.com
Media Relations: media@mirati.com



 EX-101.SCH 3 mrtx-20230817.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 mrtx-20230817_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 5 mrtx-20230817_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 image_0.jpg begin 644 image_0.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover Page
May 24, 2023
Cover [Abstract]  
Entity Central Index Key 0001576263
Amendment Flag false
Document Type 8-K
Document Period End Date Aug. 17, 2023
Entity Registrant Name MIRATI THERAPEUTICS, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-35921
Entity Tax Identification Number 46-2693615
Entity Address, Address Line One 3545 Cray Court
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code 858
Local Phone Number 332-3410
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Title of 12(b) Security Common Stock
Trading Symbol MRTX
Security Exchange Name NASDAQ
XML 8 mrtx-20230817_htm.xml IDEA: XBRL DOCUMENT 0001576263 2023-05-24 2023-05-24 0001576263 false 8-K 2023-08-17 MIRATI THERAPEUTICS, INC. DE 001-35921 46-2693615 3545 Cray Court San Diego CA 92121 858 332-3410 false false false false Common Stock MRTX NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Page Sheet http://mirati.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports mrtx-20230817.htm exhibit991-cfotransitionpr.htm mrtx-20230817.xsd mrtx-20230817_lab.xml mrtx-20230817_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mrtx-20230817.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "mrtx-20230817.htm" ] }, "labelLink": { "local": [ "mrtx-20230817_lab.xml" ] }, "presentationLink": { "local": [ "mrtx-20230817_pre.xml" ] }, "schema": { "local": [ "mrtx-20230817.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mrtx", "nsuri": "http://mirati.com/20230817", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrtx-20230817.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://mirati.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrtx-20230817.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirati.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirati.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirati.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirati.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirati.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirati.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirati.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirati.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirati.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirati.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirati.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirati.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirati.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirati.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirati.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirati.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirati.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirati.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirati.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirati.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirati.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirati.com/role/CoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001628280-23-030373-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-23-030373-xbrl.zip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end